Get started

ABT

ABT Abbott Laboratories Options Ahead of EarningsIf you haven`t bought ABT here: Then analyzing the options chain of ABT Abbott Laboratories prior to the earnings report this week, I would consider purchasing the 108usd strike price in the money Puts with an expiration date of 7/21/2023, for a premium of approximately $2.55. If these options prove to be profitable prior to the earnings release, I would sell at least half of them. Looking forward to read your opinion about it.
NYSE:ABTShort
by TopgOptions
ABT a slow moving low beta medical stockABT is Abbott Labs, a well-established medical technology company has had good earnings twice this year. In the first episode, the price trended down then recovered in a retracement. I have anchored a long-term mean VWAP and its standard deviations as a means to assess areas of dynamic support and resistance. One week ago, the price crossed the mean VWAP in its uptrend. I see this as a good place for a long trade over a month or more. For a stop loss I will place the stop below the mean VWAP also confluent with two horizontal support lines as well as the rising support trendline and the POC line of the volume profile Targets are the first and second standard deviations at about $105 and $110. I will make an optimal entry from a pivot low on a timeframe of 30-90 minutes. As the anticipated ROI is relatively small although with reasonable risk, my approach is a call option for mid-September with a strike in the range of $100-104. I expect this to yield 25% or more monthly until signs of a pullback or reversal. While the general market has heightened volatility and controlled chaos, I see adding some trades of slow-moving low beta stocks to be proper risk management.
NYSE:ABTLong
by AwesomeAvani
ABT Abbott Labs Med Tech Short Setting UpABT is shown on a 4H chart as setting up for a short trade. Demand and Summply Zones are charted by the LuxAlgo indicator. Price touched the supply zone five times in December- January then descended and touched the demand zone several times in mid-March. Fundamentally, earnings reports have been solid. Medical stocks are generally independent of the economy and recession resilient. ABT has risen off the base of bottoms at support . Relative volume exceeds that of the past year showing investor/trader interest has increased. I think it will progress to touch the supply / resistance zone another once or twice and then reverse into a solid downtrend. I see this as worth watching this upcoming week for the reversal.
NYSE:ABTShort
by AwesomeAvani
Risky Move on Abbott. ABTA collection of confluent clues. 0.786 retrace on A, quadruple pincers, low volume, RSX OBOS probably peaking, P/C ratio momentally toward green. Swing low within significant count of swing high (? Fib 1:1 ratio timewise). If it doesn't swing, stop loss is close and will not break this bank. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in green with invalidation in red. Confirmation level, where relevant, is a pink dotted, finite line. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe.
NYSE:ABTLong
by Rykin_Capital
ABT: Turnaround?Abbott Labratories Short Term - We look to Buy at 105.03 (stop at 102.52) Buying pressure has confirmed an initial rejection from the approach towards the key psychological level of 101.21. This is positive for sentiment and the uptrend has potential to return. There is scope for mild selling at the open but losses should be limited. Further upside is expected although we prefer to buy into dips close to the 105.00 level. Our profit targets will be 112.00 and 114.00 Resistance: 112.00 / 118.00 / 140.00 Support: 105.00 / 95.00 / 61.30 Please be advised that the information presented on TradingView is provided to Vantage (‘Vantage Global Limited’, ‘we’) by a third-party provider (‘Signal Centre’). Please be reminded that you are solely responsible for the trading decisions on your account. There is a very high degree of risk involved in trading. Any information and/or content is intended entirely for research, educational and informational purposes only and does not constitute investment or consultation advice or investment strategy. The information is not tailored to the investment needs of any specific person and therefore does not involve a consideration of any of the investment objectives, financial situation or needs of any viewer that may receive it. Kindly also note that past performance is not a reliable indicator of future results. Actual results may differ materially from those anticipated in forward-looking or past performance statements. We assume no liability as to the accuracy or completeness of any of the information and/or content provided herein and the Company cannot be held responsible for any omission, mistake nor for any loss or damage including without limitation to any loss of profit which may arise from reliance on any information supplied by Signal Centre.
NYSE:ABTLong
by VantageMarkets
2
Lagging Ending Diagonal on Abbott. ABTWe are probably at the end of this zigzag in that we are forming what appears to be a lagging diagonal. These tend to be final in a local correction, so it may be that this is the last short I will be putting on this one for a while. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Confirmation level, where relevant, is a pink dotted, finite line. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe.
NYSE:ABTShort
by Rykin_Capital
Abbott Labs sinking it down the sink. ABTImmediate targets 112, 109. Invalidation 133. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe
NYSE:ABTShort
by Rykin_Capital
Abbott divergent. ABTShort term outlook. Bearish outlook for gains at125, then 119. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe!
NYSE:ABTShort
by Rykin_Capital